List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6958240/publications.pdf Version: 2024-02-01



Μλατινι Κ Sλεο

#	Article	IF	CITATIONS
1	Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property. Expert Opinion on Therapeutic Patents, 2022, 32, 115-130.	2.4	9
2	Development of 3D-Printed, Liquisolid and Directly Compressed Glimepiride Tablets, Loaded with Black Seed Oil Self-Nanoemulsifying Drug Delivery System: In Vitro and In Vivo Characterization. Pharmaceuticals, 2022, 15, 68.	1.7	6
3	Molecular insight into 2-phosphoglycolate activation of the phosphatase activity of bisphosphoglycerate mutase. Acta Crystallographica Section D: Structural Biology, 2022, 78, 472-482.	1.1	4
4	Design, Synthesis, and Antisickling Investigation of a Nitric Oxide-Releasing Prodrug of 5HMF for the Treatment of Sickle Cell Disease. Biomolecules, 2022, 12, 696.	1.8	4
5	Anti-Quorum Sensing Activities of Gliptins against Pseudomonas aeruginosa and Staphylococcus aureus. Biomedicines, 2022, 10, 1169.	1.4	23
6	Metabolic Reprogramming in Sickle Cell Diseases: Pathophysiology and Drug Discovery Opportunities. International Journal of Molecular Sciences, 2022, 23, 7448.	1.8	2
7	New Antiproliferative Triflavanone from Thymelaea hirsuta—Isolation, Structure Elucidation and Molecular Docking Studies. Molecules, 2021, 26, 739.	1.7	7
8	MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease. Blood Advances, 2021, 5, 1388-1402.	2.5	4
9	Inborn errors in the vitamin B6 salvage enzymes associated with neonatal epileptic encephalopathy and other pathologies. Biochimie, 2021, 183, 18-29.	1.3	16
10	3D Interaction Homology: Hydropathic Analyses of the "π–Cation―and "π–π―Interaction Motifs Phenylalanine, Tyrosine, and Tryptophan Residues. Journal of Chemical Information and Modeling, 2021, 61, 2937-2956.	in 2.5	11
11	Not Only Antimicrobial: Metronidazole Mitigates the Virulence of Proteus mirabilis Isolated from Macerated Diabetic Foot Ulcer. Applied Sciences (Switzerland), 2021, 11, 6847.	1.3	32
12	Improving the Solubility and Oral Bioavailability of a Novel Aromatic Aldehyde Antisickling Agent (PP10) for the Treatment of Sickle Cell Disease. Pharmaceutics, 2021, 13, 1148.	2.0	4
13	Discovery of novel quinoline-based analogues of combretastatin A-4 as tubulin polymerisation inhibitors with apoptosis inducing activity and potent anticancer effect. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 802-818.	2.5	15
14	Chemical Composition of the Red Sea Green Algae Ulva lactuca: Isolation and In Silico Studies of New Anti-COVID-19 Ceramides. Metabolites, 2021, 11, 816.	1.3	8
15	Umuhengerin Neuroprotective Effects in Streptozotocin-Induced Alzheimer's Disease Mouse Model via Targeting Nrf2 and NF-Kβ Signaling Cascades. Antioxidants, 2021, 10, 2011.	2.2	9
16	X-ray crystal structure of a 2-amino-3,4-dihydroquinazoline 5-HT3 serotonin receptor antagonist and related analogs. Journal of Molecular Structure, 2020, 1202, 127276.	1.8	0
17	Major flavonoids from Psiadia punctulata produce vasodilation via activation of endothelial dependent NO signaling. Journal of Advanced Research, 2020, 24, 273-279.	4.4	14
18	Osteoprotective Activity and Metabolite Fingerprint via UPLC/MS and GC/MS of Lepidium sativum in Ovariectomized Rats. Nutrients, 2020, 12, 2075.	1.7	12

#	Article	IF	CITATIONS
19	Exploration of Structure–Activity Relationship of Aromatic Aldehydes Bearing Pyridinylmethoxy-Methyl Esters as Novel Antisickling Agents. Journal of Medicinal Chemistry, 2020, 63, 14724-14739.	2.9	7
20	An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling. Biomolecules, 2020, 10, 1508.	1.8	6
21	Euphorbia cuneata Represses LPS-Induced Acute Lung Injury in Mice via Its Antioxidative and Anti-Inflammatory Activities. Plants, 2020, 9, 1620.	1.6	8
22	Effective and Versatile Synthesis of Ginkgotoxin and Its 4′-O-Derivatives through Regioselective 4′-O-Alkylation and 4′-O-Chlorination of 3,5′-O-Dibenzylpyridoxine. SynOpen, 2020, 04, 51-54.	0.8	1
23	VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditions. Scientific Reports, 2020, 10, 20277.	1.6	14
24	Introducing of potent cytotoxic novel 2-(aroylamino)cinnamamide derivatives against colon cancer mediated by dual apoptotic signal activation and oxidative stress. Bioorganic Chemistry, 2020, 101, 103953.	2.0	4
25	Investigating the Potential of Transmucosal Delivery of Febuxostat from Oral Lyophilized Tablets Loaded with a Self-Nanoemulsifying Delivery System. Pharmaceutics, 2020, 12, 534.	2.0	14
26	Structural elucidation and in vivo anti-arthritic activity of β-amyrin and polpunonic acid isolated from the root bark of Ziziphus abyssinica HochstEx. A Rich (Rhamnaceae). Bioorganic Chemistry, 2020, 98, 103744.	2.0	14
27	<p>Enhancement of Simvastatin ex vivo Permeation from Mucoadhesive Buccal Films Loaded with Dual Drug Release Carriers</p> . International Journal of Nanomedicine, 2020, Volume 15, 4001-4020.	3.3	16
28	Hemoglobin: Structure, Function and Allostery. Sub-Cellular Biochemistry, 2020, 94, 345-382.	1.0	106
29	Structural modification of azolylacryloyl derivatives yields a novel class of covalent modifiers of hemoglobin as potential antisickling agents. MedChemComm, 2019, 10, 1900-1906.	3.5	6
30	3D interaction homology: The hydropathic interaction environments of even alanine are diverse and provide novel structural insight. Journal of Structural Biology, 2019, 207, 183-198.	1.3	8
31	Psiadia punctulata major flavonoids alleviate exaggerated vasoconstriction produced by advanced glycation end products. PLoS ONE, 2019, 14, e0222101.	1.1	11
32	Pyridoxamine Supplementation Effectively Reverses the Abnormal Phenotypes of Zebrafish Larvae With PNPO Deficiency. Frontiers in Pharmacology, 2019, 10, 1086.	1.6	5
33	<p>Zein-alpha lipoic acid-loaded nanoparticles to enhance the oral bioavailability of dapoxetine: optimization and clinical pharmacokinetic evaluation</p> . International Journal of Nanomedicine, 2019, Volume 14, 7461-7473.	3.3	7
34	Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients. American Journal of Hematology, 2019, 94, 575-584.	2.0	47
35	PP-14, a Novel Structurally-Enhanced Antisickling Allosteric Hemoglobin Effector, Increases Oxygen Affinity and Disrupts Hemoglobin S Polymer Formation. Blood, 2019, 134, 73-73.	0.6	1
36	Rational design of pyridyl derivatives of vanillin for the treatment of sickle cell disease. Bioorganic and Medicinal Chemistry, 2018, 26, 2530-2538.	1.4	26

#	Article	IF	CITATIONS
37	A Triazole Disulfide Compound Increases the Affinity of Hemoglobin for Oxygen and Reduces the Sickling of Human Sickle Cells. Molecular Pharmaceutics, 2018, 15, 1954-1963.	2.3	18
38	Rational modification of vanillin derivatives to stereospecifically destabilize sickle hemoglobin polymer formation. Acta Crystallographica Section D: Structural Biology, 2018, 74, 956-964.	1.1	15
39	Design, Synthesis, and Biological Evaluation of Allosteric Effectors That Enhance CO Release from Carboxyhemoglobin. ACS Medicinal Chemistry Letters, 2018, 9, 714-718.	1.3	5
40	LC-MS Analysis of Anti-Sickling Compounds in Cord Blood Derived RBCs Demonstrates Modification of Fetal Hemoglobin and Globin Chain Binding Preferences. Blood, 2018, 132, 1074-1074.	0.6	0
41	Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease. Molecular Pharmaceutics, 2017, 14, 3499-3511.	2.3	39
42	Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease. Scientific Reports, 2017, 7, 15281.	1.6	47
43	Maintaining pH-dependent conformational flexibility of M1 is critical for efficient influenza A virus replication. Emerging Microbes and Infections, 2017, 6, 1-11.	3.0	11
44	Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin. Molecules, 2016, 21, 1057.	1.7	4
45	Inactive mutants of human pyridoxine 5′â€phosphate oxidase: a possible role for a noncatalytic pyridoxal 5′â€phosphate tight binding site. FEBS Open Bio, 2016, 6, 398-408.	1.0	15
46	Characterization of the mixed axial ligand complex (4-cyanopyridine)(imidazole)(tetramesitylporphinato)iron(iii) perchlorate. Stabilization by synergic bonding. Journal of Porphyrins and Phthalocyanines, 2016, 20, 254-264.	0.4	1
47	New developments in antiâ€sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin <i>inÂvivo</i> ?. British Journal of Haematology, 2016, 175, 24-30.	1.2	58
48	Crystal structure of carbonmonoxy sickle hemoglobin in R-state conformation. Journal of Structural Biology, 2016, 194, 446-450.	1.3	30
49	Sphingosine-1-phosphate promotes erythrocyte glycolysis and oxygen release for adaptation to high-altitude hypoxia. Nature Communications, 2016, 7, 12086.	5.8	163
50	Broad Spectrum Anti-Influenza Agents by Inhibiting Self-Association of Matrix Protein 1. Scientific Reports, 2016, 6, 32340.	1.6	10
51	Development of a Triazolyldisulfide Compound That Increases the Affinity of Hemoglobin for Oxygen and Reduces Hypoxic Sickling of Sickle Cells. Blood, 2016, 128, 3642-3642.	0.6	1
52	Vzhe-039, a Novel Structurally-Enhanced Allosteric Hemoglobin Effector Inhibits Sickling of SS Erythrocytes In Vitro, and Exhibits Improved Pharmacologic Properties In Vivo. Blood, 2016, 128, 3645-3645.	0.6	2
53	Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease. Blood, 2016, 128, 2474-2474.	0.6	0
54	3d interaction homology: The structurally known rotamers of tyrosine derive from a surprisingly limited set of information-rich hydropathic interaction environments described by maps. Proteins: Structure, Function and Bioinformatics, 2015, 83, 1118-1136.	1.5	10

#	Article	IF	CITATIONS
55	Identification of a novel class of covalent modifiers of hemoglobin as potential antisickling agents. Organic and Biomolecular Chemistry, 2015, 13, 6353-6370.	1.5	16
56	Molecular basis of E. coli l-threonine aldolase catalytic inactivation at low pH. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 278-283.	1.1	7
57	A Plasmid-Borne System To Assess the Excision and Integration of Staphylococcal Cassette Chromosome mec Mediated by CcrA and CcrB. Journal of Bacteriology, 2015, 197, 2754-2761.	1.0	6
58	Structural basis for the antipolymer activity of Hbζ2βs2trapped in a tense conformation. Journal of Molecular Structure, 2015, 1099, 99-107.	1.8	3
59	Design, Synthesis, and Investigation of Novel Nitric Oxide (NO)-Releasing Prodrugs as Drug Candidates for the Treatment of Ischemic Disorders: Insights into NO-Releasing Prodrug Biotransformation and Hemoglobin–NO Biochemistry. Biochemistry, 2015, 54, 7178-7192.	1.2	9
60	Therapeutic Strategies to Alter the Oxygen Affinity of Sickle Hemoglobin. Hematology/Oncology Clinics of North America, 2014, 28, 217-231.	0.9	65
61	On the catalytic mechanism and stereospecificity of <i><scp>E</scp>scherichiaÂcoli </i> <scp>l</scp> â€threonine aldolase. FEBS Journal, 2014, 281, 129-145.	2.2	57
62	Identification of a Small Molecule that Increases Hemoglobin Oxygen Affinity and Reduces SS Erythrocyte Sickling. ACS Chemical Biology, 2014, 9, 2318-2325.	1.6	44
63	Predicting the molecular interactions of CRIP1a–cannabinoid 1 receptor with integrated molecular modeling approaches. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1158-1165.	1.0	13
64	Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression. Journal of Clinical Investigation, 2014, 124, 2750-2761.	3.9	112
65	Novel Structurally-Modified Allosteric Effectors of Hemoglobin Exhibit Superior Antisickling Properties. Blood, 2014, 124, 218-218.	0.6	2
66	Crystal Structures of Influenza A Virus Matrix Protein M1: Variations on a Theme. PLoS ONE, 2014, 9, e109510.	1.1	32
67	Liganded Hb ζ2βS2 Exhibits Antipolymer Activity Despite a T-like Quaternary Structure. Blood, 2014, 124, 4062-4062.	0.6	0
68	Unintended consequences? Water molecules at biological and crystallographic protein–protein interfaces. Computational Biology and Chemistry, 2013, 47, 126-141.	1.1	14
69	Characterization of the Staphylococcus aureus rRNA Methyltransferase Encoded by orfX, the Gene Containing the Staphylococcal Chromosome Cassette mec (SCCmec) Insertion Site. Journal of Biological Chemistry, 2013, 288, 132-140.	1.6	61
70	Structure of fully liganded Hb ζ2β2strapped in a tense conformation. Acta Crystallographica Section D: Biological Crystallography, 2013, 69, 2061-2071.	2.5	5
71	Methemoglobinemia In Rhesus Monkeys Due To M-Hemoglobinopathy. Blood, 2013, 122, 4696-4696.	0.6	0
72	Characterization of DNA Sequences Required for the CcrAB-Mediated Integration of Staphylococcal Cassette Chromosome <i>mec</i> , a Staphylococcus aureus Genomic Island. Journal of Bacteriology, 2012, 194, 486-498.	1.0	24

#	Article	IF	CITATIONS
73	Zebrafish larvae exposed to ginkgotoxin exhibit seizure-like behavior that is relieved by pyridoxal-5′-phosphate, GABA and anti-epileptic drugs. DMM Disease Models and Mechanisms, 2012, 5, 785-795.	1.2	29
74	Crystal Structures of Human Pyridoxal Kinase in Complex with the Neurotoxins, Ginkgotoxin and Theophylline: Insights into Pyridoxal Kinase Inhibition. PLoS ONE, 2012, 7, e40954.	1.1	28
75	Pyridoxal 5′-Phosphate Is a Slow Tight Binding Inhibitor of E. coli Pyridoxal Kinase. PLoS ONE, 2012, 7, e41680.	1.1	48
76	In Silico-Screening Approaches for Lead Generation: Identification of Novel Allosteric Modulators of Human-Erythrocyte Pyruvate Kinase. Methods in Molecular Biology, 2012, 796, 351-367.	0.4	0
77	Inhibition of Sphk1 Activity in Erythrocytes Ameliorating the Pathophysiology of Sickle Cell Disease. Blood, 2012, 120, 822-822.	0.6	7
78	Vitamin B6 salvage enzymes: Mechanism, structure and regulation. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 1597-1608.	1.1	178
79	Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin. Acta Crystallographica Section D: Biological Crystallography, 2011, 67, 920-928.	2.5	41
80	Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillin. Corrigendum. Acta Crystallographica Section D: Biological Crystallography, 2011, 67, 1076-1076.	2.5	4
81	Hemoglobin–ligand binding: Understanding Hb function and allostery on atomic level. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2011, 1814, 797-809.	1.1	76
82	Hb Lake Tapawingo [α46(CE4)Phe→Ser; HBA2:c.140T>C]: A New Unstable α Chain Hemoglobin Variant Associated with Low Systemic Arterial Saturation. Hemoglobin, 2011, 35, 411-416.	0.4	0
83	Hb Baden: Structural and functional characterization. American Journal of Hematology, 2010, 85, 848-852.	2.0	4
84	Chlorido(2,3,7,8,12,13,17,18-octaethylporphyrinato)iron(III) dichloromethane sesquisolvate. Acta Crystallographica Section E: Structure Reports Online, 2010, 66, m733-m733.	0.2	4
85	Molecular Basis of Reduced Pyridoxine 5′-Phosphate Oxidase Catalytic Activity in Neonatal Epileptic Encephalopathy Disorder. Journal of Biological Chemistry, 2009, 284, 30949-30956.	1.6	41
86	Structure of relaxed-state human hemoglobin: insight into ligand uptake, transport and release. Acta Crystallographica Section D: Biological Crystallography, 2009, 65, 41-48.	2.5	31
87	Kinetic and structural studies of the role of the active site residue Asp235 of human pyridoxal kinase. Biochemical and Biophysical Research Communications, 2009, 381, 12-15.	1.0	25
88	Pyridyl Derivatives of Benzaldehyde as Potential Antisickling Agents. Chemistry and Biodiversity, 2008, 5, 1762-1769.	1.0	38
89	Expression of Ral GTPases, Their Effectors, and Activators in Human Bladder Cancer. Clinical Cancer Research, 2007, 13, 3803-3813.	3.2	78
90	Identification of Novel Allosteric Regulators of Humanâ€Erythrocyte Pyruvate Kinase. Chemistry and Biodiversity, 2007, 4, 2603-2617.	1.0	4

#	Article	IF	CITATIONS
91	Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2581-2589.	1.0	23
92	Crystal Structure of human pyridoxal kinase: Structural basis of M <sup>+</sup> and M <sup>2+</sup> activation. Protein Science, 2007, 16, 2184-2194.	3.1	38
93	Structure of the MecI repressor fromStaphylococcus aureusin complex with the cognate DNA operator ofmec. Acta Crystallographica Section F: Structural Biology Communications, 2006, 62, 320-324.	0.7	19
94	Crystal Structure of Pyridoxal Kinase from the Escherichia coli pdxK Gene: Implications for the Classification of Pyridoxal Kinases. Journal of Bacteriology, 2006, 188, 4542-4552.	1.0	56
95	5-hydroxymethyl-2-furfural modifies intracellular sickle haemoglobin and inhibits sickling of red blood cells. British Journal of Haematology, 2005, 128, 552-561.	1.2	211
96	Structures of R- and T-state hemoglobin Bassett: elucidating the structural basis for the low oxygen affinity of a mutant hemoglobin. Acta Crystallographica Section D: Biological Crystallography, 2005, 61, 156-162.	2.5	6
97	Structure ofEscherichia colipyridoxine 5′-phosphate oxidase in a tetragonal crystal form: insights into the mechanistic pathway of the enzyme. Acta Crystallographica Section D: Biological Crystallography, 2005, 61, 599-604.	2.5	11
98	Crystal Structures of the Blal Repressor from Staphylococcus aureus and Its Complex with DNA: Insights into Transcriptional Regulation of the bla and mec Operons. Journal of Bacteriology, 2005, 187, 1833-1844.	1.0	62
99	The Enigma of the Liganded Hemoglobin End State:  A Novel Quaternary Structure of Human Carbonmonoxy Hemoglobin,. Biochemistry, 2005, 44, 8347-8359.	1.2	96
100	Properties of human and rabbit cytosolic serine hydroxymethyltransferase are changed by single nucleotide polymorphic mutations. Archives of Biochemistry and Biophysics, 2005, 442, 92-101.	1.4	22
101	In Vitro Antisickling Effects of Novel Pyridyl Derivatives with Enhanced Potency Blood, 2005, 106, 2347-2347.	0.6	5
102	Various Drugs with or without an Antisickling Effect in the In Vitro Tests Showed a Strong Antisickling Effect in the In Vivo Studies in Transgenic Sickle Mice Blood, 2005, 106, 3190-3190.	0.6	0
103	Crystal Structure of the PdxY Protein from Escherichia coli. Journal of Bacteriology, 2004, 186, 8074-8082.	1.0	37
104	Characterization of hemoglobin bassett (?94Asp?Ala), a variant with very low oxygen affinity. American Journal of Hematology, 2004, 77, 268-276.	2.0	25
105	Serine Hydroxymethyltransferase:Â Role of Glu75 and Evidence that Serine Is Cleaved by a Retroaldol Mechanismâ€. Biochemistry, 2004, 43, 6865-6876.	1.2	61
106	Structural Basis for the Potent Antisickling Effect of a Novel Class of Five-Membered Heterocyclic Aldehydic Compounds. Journal of Medicinal Chemistry, 2004, 47, 4665-4676.	2.9	80
107	MSDD1, a Prodrug of 5-Hydroxymethyl-2-Furfural (5HMF), Prolongs the Antisickling Effect of 5HMF in Transgenic Sickle Mice Blood, 2004, 104, 3576-3576.	0.6	1
108	Structure and mechanism of Escherichia coli pyridoxine 5′-phosphate oxidase. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2003, 1647, 76-82.	1.1	57

#	Article	IF	CITATIONS
109	Structure and properties of recombinant human pyridoxine 5′-phosphate oxidase. Protein Science, 2003, 12, 1455-1463.	3.1	82
110	Role of Proline Residues in the Folding of Serine Hydroxymethyltransferase. Journal of Biological Chemistry, 2003, 278, 31088-31094.	1.6	22
111	X-ray Crystallography of Hemoglobins. , 2003, 82, 001-019.		21
112	Active site structure and stereospecificity of Escherichia coli pyridoxine-5′-phosphate oxidase. Journal of Molecular Biology, 2002, 315, 385-397.	2.0	37
113	Synthesis and X-ray Studies of Chiral Allosteric Modifiers of Hemoglobin. Journal of Medicinal Chemistry, 2002, 45, 1184-1195.	2.9	18
114	X-ray crystallographic analyses of symmetrical allosteric effectors of hemoglobin: compounds designed to link primary and secondary binding sites. Acta Crystallographica Section D: Biological Crystallography, 2002, 58, 634-644.	2.5	11
115	Structure of human carbonmonoxyhemoglobin at 2.16â€Ã: a snapshot of the allosteric transition. Acta Crystallographica Section D: Biological Crystallography, 2002, 58, 2031-2037.	2.5	26
116	Control of the allosteric equilibrium of hemoglobin by cross-linking agents. Protein Science, 2002, 11, 1376-1383.	3.1	8
117	X-ray structure of Escherichia coli pyridoxine 5′-phosphate oxidase complexed with pyridoxal 5′-phosphate at 2.0 à resolution. Journal of Molecular Biology, 2001, 310, 817-826.	2.0	37
118	Structure of tetragonal crystals of human erythrocyte catalase. Acta Crystallographica Section D: Biological Crystallography, 2001, 57, 1-7.	2.5	22
119	The X-ray structure determination of bovine carbonmonoxy hemoglobin at 2.1 Ã resoultion and its relationship to the quaternary structures of other hemoglobin crystal forms. Protein Science, 2001, 10, 1091-1099.	3.1	41
120	High-resolution crystal structure of deoxy hemoglobin complexed with a potent allosteric effector. Protein Science, 2001, 10, 951-957.	3.1	60
121	Structure of human erythrocyte catalase. Acta Crystallographica Section D: Biological Crystallography, 2000, 56, 241-245.	2.5	55
122	X-ray structure of Escherichia coli pyridoxine 5′-phosphate oxidase complexed with FMN at 1.8 Ã resolution. Structure, 2000, 8, 751-762.	1.6	29
123	Synthesis and Structureâ^Activity Relationships of Chiral Allosteric Modifiers of Hemoglobin#. Journal of Medicinal Chemistry, 2000, 43, 4726-4737.	2.9	22
124	Models of the Cytochromes. Axial Ligand Orientation and Complex Stability in Iron(II) Porphyrinates:Â The Case of the Noninteracting dπOrbitals. Journal of the American Chemical Society, 1997, 119, 9438-9448.	6.6	84
125	The transactivation region of the Fis protein that controls site-specific DNA inversion contains extended mobile beta -hairpin arms. EMBO Journal, 1997, 16, 6860-6873.	3.5	52
126	The crystal structure of the immunity protein of colicin E7 suggests a possible colicin-interacting surface Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 6437-6442.	3.3	51

#	Article	IF	CITATIONS
127	Crystallization and preliminary X-ray crystallographic analysis of ImmE7 protein of colicin E7. Proteins: Structure, Function and Bioinformatics, 1995, 23, 588-590.	1.5	3
128	How Allosteric Effectors Can Bind to the Same Protein Residue and Produce Opposite Shifts in the Allosteric Equilibrium. Biochemistry, 1995, 34, 15006-15020.	1.2	44
129	Bisaldehyde Allosteric Effectors as Molecular Ratchets and Probes. Biochemistry, 1995, 34, 15021-15036.	1.2	36
130	Axial Ligand Orientation in Iron(III) Porphyrinates: Effect of Axial .piAcceptors. Characterization of the Low-Spin Complex [Fe(TPP)(4-CNPy)2]ClO4. Journal of the American Chemical Society, 1994, 116, 7760-7770.	6.6	164
131	Synthesis, Structure, and Characterization of Five-Coordinate Aquo(octaethylporphinato)iron(III) Perchlorate. Inorganic Chemistry, 1994, 33, 1319-1324.	1.9	30
132	The effect of axial π-acceptor ligands in iron(III) porphyrinates. Characterization of the low-spin derivative [Fe(TPP)(4-CNPy)2]ClO4, a heme complex with an axial EPR spectrum Journal of Inorganic Biochemistry, 1993, 51, 164.	1.5	0
133	Models of the cytochromes b. Low-spin bis-ligated (porphinato)iron(III) complexes with unusual molecular structures and NMR, EPR, and Moessbauer spectra. Journal of the American Chemical Society, 1992, 114, 7066-7075.	6.6	150
134	Characterization of iron octaethylporphyrin .pication radicals. Inorganic Chemistry, 1992, 31, 939-941.	1.9	33
135	New class of bridged diiron(III) complexes with a single hydroxo bridge. The preparation and structure of (.muhydroxo)bis((octaethylporphinato)iron(III)) perchlorate. Journal of the American Chemical Society, 1992, 114, 4420-4421.	6.6	101
136	Models of the cytochromes b. Control of axial ligand orientation with a hindered porphyrin system. Journal of the American Chemical Society, 1991, 113, 5497-5510.	6.6	153
137	Models of cytochromes b. Attempts to control axial ligand orientation with a "hindered" porphyrin system. Inorganic Chemistry, 1991, 30, 1643-1650.	1.9	68
138	Characterization of the admixed intermediate-spin complex bis(3-cyanopyridine) (octaethylporphinato)iron(III) perchlorate. Inorganica Chimica Acta, 1991, 184, 251-258.	1.2	10
139	Molecular structure of bis(1-methylimidazole)(meso-tetraphenylporphinato)iron(III) perchlorate. Inorganica Chimica Acta, 1990, 178, 261-267.	1.2	44
140	Axial ligand orientation in iron(II) porphyrinates. Preparation and characterization of low-spin bis(imidazole)(tetraphenylporphyrinato)iron(II) complexes. Inorganic Chemistry, 1990, 29, 626-633.	1.9	62